Related Experiment Video

Updated: Jul 20, 2025

Identification of Neutrophil Extracellular Traps in Paraffin-Embedded Feline Arterial Thrombi using Immunofluorescence Microscopy
08:48

Identification of Neutrophil Extracellular Traps in Paraffin-Embedded Feline Arterial Thrombi using Immunofluorescence Microscopy

Published on: March 29, 2020

8.6K

Preventing Cardiogenic Thromboembolism in Cats: Literature Gaps, Rational Recommendations, and Future Therapies

Meg Shaverdian1, Ronald H L Li2

  • 1Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, 2108 Tupper Hall, One Shields Avenue, Davis, CA 95616, USA.

The Veterinary Clinics of North America. Small Animal Practice
|July 29, 2023
PubMed

Insights

Cardiogenic arterial thromboembolism (CATE) in cats with heart disease causes high mortality. Further understanding of CATE

Area of Science:

  • Veterinary Cardiology
  • Thrombosis Research

Background:

  • Cardiogenic arterial thromboembolism (CATE) is a severe complication in cats suffering from cardiomyopathies.
  • CATE leads to significant morbidity and mortality, with high rates of recurrence and death despite current treatments.

Purpose of the Study:

  • To comprehensively review the existing literature on the pathophysiology, diagnosis, and management of CATE in cats.
  • To identify knowledge gaps and research priorities concerning the roles of immunothrombosis and procoagulant platelets in CATE pathogenesis.

Main Methods:

  • Systematic literature review of studies on feline CATE.
  • Analysis of current diagnostic and therapeutic recommendations.
  • Identification of research gaps in CATE pathogenesis.

Main Results:

  • Existing literature highlights high recurrence and mortality rates for CATE in cats.
  • Current understanding of CATE pathophysiology, particularly the roles of immunothrombosis and procoagulant platelets, remains incomplete.
  • There is a critical need for further research into novel diagnostic and therapeutic strategies.

Conclusions:

  • Further research into the pathophysiology of CATE, focusing on immunothrombosis and procoagulant platelets, is essential.
  • Developing novel diagnostic tests and therapeutics is crucial to improve outcomes for cats with CATE.
  • Addressing knowledge gaps will aid in reducing the morbidity and mortality associated with this devastating complication.

Keywords:
Hypertrophic cardiomyopathyImmunothrombosisNeutrophil extracellular trapsPlatelet primingThromboprophylaxis

More Related Videos

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

1.3K
Ferric Chloride-induced Canine Carotid Artery Thrombosis: A Large Animal Model of Vascular Injury08:39

Ferric Chloride-induced Canine Carotid Artery Thrombosis: A Large Animal Model of Vascular Injury

Published on: September 7, 2018

9.3K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
10
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
563
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16